Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2016: Volume 21/ Issue 5 Article 5
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 21, Issue 5, 04 February 2016
News
Eurosurveillance editorial team: Resources and latest news about Zika virus disease available from ECDC

+ Author affiliations


Citation style for this article: Eurosurveillance editorial team. Resources and latest news about Zika virus disease available from ECDC. Euro Surveill. 2016;21(5):pii=30128. DOI: http://dx.doi.org/10.2807/1560-7917.ES.2016.21.5.30128


On 1 February 2016, the World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) following a meeting of the recently established ‘International Health Regulations (2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations’ and the rapid spread of the disease in the Americas [1]. At the meeting, the Committee advised that the recent cluster of microcephaly cases and other neurologic disorders reported in Brazil, following a similar cluster in French Polynesia in 2014, constitutes a PHEIC.

The European Centre for Disease Prevention and Control (ECDC) has monitored the Zika outbreaks in the Pacific Region and Latin America since onset of the respective outbreaks, and provides updates and resources in various formats such as daily updated maps of the countries and territories with reported confirmed autochthonous cases of Zika virus infection [2], fact sheets for professionals, risk assessments and epidemiological updates reflecting changes in the evolution of the epidemic [3] on its website. The weekly ECDC communicable disease threat report, summarises information gathered through epidemic intelligence by ECDC regarding communicable disease threats of concern to the European Union. It also includes updated information on the global situation and changes in the epidemiology of Zika virus [4].

As of 4 February 2016, no autochthonous Zika virus transmission had been reported in the continental European Union (EU). In 2015 and 2016, in several EU countries there were imported cases who had recently travelled in affected countries/territories. Several outermost EU regions continue to report Zika virus autochthonous circulation: French Guiana Guadeloupe, Martinique, Saint Martin and, Curacao (an independent state and part of the Kingdom of the Netherlands) reported an autochthonous case [2]. Widespread transmission is also present in Cape Verde and sporadic Zika virus outbreaks have been described in Africa and South Asia since the virus was discovered for the first time in Uganda in 1947. In 2013‒14 a large outbreak occurred in the Pacific region, especially in French Polynesia. In 2015, the Pacific region experienced another outbreak and in May 2015, the Pan American Health Organization (PAHO) and several Latin American authorities reported cases. The recent outbreaks in French Polynesia, Brazil and other Latin America countries led to reports of potential neurological and auto-immune complications of Zika virus disease. Moreover, in Brazil and in other countries in Latin America, there were signals that a strong association between Zika virus infection and congenital abnormalities, including microcephaly, could exist when pregnant women were infected.

Read more in the articles published on Zika virus infection in Eurosurveillance.



References

  1. World Health Organization (WHO). WHO statement on the first meeting of the International Health Regulations (2005) (IHR 2005) Emergency Committee on Zika virus and observed increase in neurological disorders and neonatal malformations. Geneva: WHO; 2016. Available from: http://www.who.int/mediacentre/news/statements/2016/1st-emergency-committee-zika/en/

  2. European Centre for Disease Prevention and Control (ECDC). Epidemiological update: Outbreaks of Zika virus and complications potentially linked to the Zika virus infection. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/press/news/_layouts/forms/News_DispForm.aspx?ID=1350&List=8db7286c-fe2d-476c-9133-18ff4cb1b568&Source=http%3A%2F%2Fecdc%2Eeuropa%2Eeu%2Fen%2FPages%2Fhome%2Easpx

  3. European Centre for Disease Prevention and Control (ECDC). Zika virus infection. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/healthtopics/zika_virus_infection/Pages/index.aspx

  4. European Centre for Disease Prevention and Control (ECDC). Communicable Disease Threat Reports. Stockholm: ECDC; 2016. Available from: http://ecdc.europa.eu/en/publications/surveillance_reports/communicable-disease-threats-report/Pages/cdtr.aspx



Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.